Phibro Animal Health | PAHC - 销售收入

金融业

USD

USD 1.45B

现金及等价物

USD 54.93M

USD 240.42M

USD 894.07M

USD 281.87M

USD 474.17M

股息收益率

1.29

USD 54.99M

USD 68.1M

1.92K

EPS每股收益

USD 0.78

股本和储备

USD 361.83M

USD 133.5M

债务利息支出

USD 11.91M

USD 0.08

USD 597.69M

USD 1.31B

USD 27.46M

USD 361.83M

USD 54.99M

普通股股本

USD 40.48M

13.82

USD 38.63M

USD 373.91M

销售和管理费用

USD 78.32M

USD 539.7M

贸易债权人

USD 129.64M

应收帐款人

USD 215.87M

	销售	更改		日
Align Technology	USD 1.04B		10M	2026-03
ANI Pharmaceuticals	USD 237.5M		9.56M	2026-03
Aurora Cannabis	CAD 38.01M		56.18M	2026-03
Bristol-Myers Squibb	USD 11.49B		1.01B	2026-03
Canopy Growth	CAD 71.25M		3.29M	2026-03
Corcept Therapeutics	USD 164.9M		37.22M	2026-03
Eli Lilly	USD 19.8B		500M	2026-03
Henry Schein	USD 3.37B		30M	2026-03
Idexx Laboratories	USD 1.14B		50M	2026-03
Knight Therapeutics	CAD 133.11M		11.56M	2025-12
Merck	USD 16.29B		110M	2026-03
Nektar Therapeutics	USD 21.81M		2.32M	2025-12
Pacira	USD 177M		19.87M	2026-03
Phibro Animal Health	USD 373.91M		10.02M	2025-12
Prestige Brands	USD 281.62M		1.82M	2026-03
Supernus Pharmaceuticals	USD 207.71M		3.89M	2026-03
Zoetis	USD 2.3B		100M	2026-03